Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →A grade PMID 42248607
View analysis →A grade PMID 42260111
View analysis →A grade PMID 42296977
View analysis →A grade PMID 42308229
View analysis →A grade PMID 42032072
View analysis →This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 37.0/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 37.0/100. Study design: 35.0; human relevance: 20.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 35.9/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 22.0; sample size: 20.0; recency: 65.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 35.0/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 35.0/100. Study design: 35.0; human relevance: 20.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 35.0/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 65.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 34.1/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 18.0; sample size: 20.0; recency: 100.0; abstract quality: 40.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 31.7/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 26.2; sample size: 20.0; recency: 100.0; abstract quality: 0.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 31.7/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 26.2; sample size: 20.0; recency: 100.0; abstract quality: 0.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 30.7/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 20.8; sample size: 20.0; recency: 100.0; abstract quality: 0.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 30.1/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 18.1; sample size: 20.0; recency: 100.0; abstract quality: 0.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 30.1/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 18.1; sample size: 20.0; recency: 100.0; abstract quality: 0.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 30.1/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 18.1; sample size: 20.0; recency: 100.0; abstract quality: 0.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 30.1/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 18.1; sample size: 20.0; recency: 100.0; abstract quality: 0.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 28.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 0.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 28.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 0.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 28.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 0.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 28.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 0.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 28.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 0.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 28.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 0.0.
